Retrospective study of the total insertion period of peripherally inserted central catheter: discussion of anti-thrombogenic surface and other biomaterial requirements.
A retrospective study of patients' records on reviewing the purpose of venous catheter insertion (chemotherapy, blood transfusion, antibiotics or parenteral nutrition); total period of insertion; reason for catheter removal. 120 admitted patients who received fluoroscopic guide PICC (4-French single lumen silicone rubber catheter) insertions into distal SVC via antecubital region of forearm. We retrospectively review human factors including the patients' laboratory data of pre- and post-insertion, total insertion period and reasons for withdrawal. The important human factors that affect the clinical outcome of PICC were also evaluated. The results indicated that the most common complications were wound oozing, phlebitis, occlusion, infection and leaking. Persistent wound oozing for over 3-day-period is the higher incidence of complication. It also demonstrated a surprisingly high ratio (> 77%) in those patients with thrombocytopenia and leukemia. In this group, persistent low platelet counts could be noted, the ratio of failure (remove PICC within 3 days) is 10% and there is 40% decrease insertion period (< 30 days). Prospectively, it is worthwhile to choose new material or new technology of surface coating of PICC, to decrease consumption of platelet thrombogenic proteins and to maintain normal coagulate function of human bodies.
Leung
Ting-Kai
TK
Diagnostic Radiology Department of Taipei Medical University Hospital, Taipei Medical University, No. 252, Wu Hsing Street (110) Taipei, Taiwan, Taiwan, ROC.
Chang
Chih-Pong
CP
Lee
Chi-Ming
CM
Shen
Li-Kuo
LK
D002405:Catheterization, Central Venous / Q000295:instrumentation* / Q000379:methods / Q000706:statistics & numerical data; D002408:Catheters, Indwelling / Q000706:statistics & numerical data*; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage; D015897:Comorbidity; D004868:Equipment Failure / Q000706:statistics & numerical data; D005343:Fibrinolytic Agents / Q000008:administration & dosage; D006801:Humans; D015994:Incidence; D010689:Phlebitis / Q000453:epidemiology*; D012189:Retrospective Studies; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D013499:Surface Properties; D013624:Taiwan / Q000453:epidemiology; D013921:Thrombocytopenia / Q000453:epidemiology* / Q000517:prevention & control*; D013997:Time Factors; D016896:Treatment Outcome
D020099:Coated Materials, Biocompatible; D005343:Fibrinolytic Agents